{"id":"bet-inhibitor","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BET proteins play a key role in the regulation of gene transcription, and their inhibition has been shown to have anti-inflammatory and anti-cancer effects.","oneSentence":"BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:59.595Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"T-cell lymphoma"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05053971","phase":"PHASE1, PHASE2","title":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma","enrollment":49},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT05327010","phase":"PHASE2","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-14","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":88},{"nctId":"NCT05803382","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-08","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8","enrollment":30},{"nctId":"NCT05950464","phase":"PHASE1","title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-18","conditions":"Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma","enrollment":60},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT06102902","phase":"PHASE1","title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-05","conditions":"Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT04279847","phase":"PHASE1","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-02-23","conditions":"Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome","enrollment":140},{"nctId":"NCT03222609","phase":"PHASE2","title":"A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-31","conditions":"Myelofibrosis (MF)","enrollment":191},{"nctId":"NCT04587479","phase":"PHASE1","title":"A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2020-11-23","conditions":"Solid Tumors, Adult","enrollment":41},{"nctId":"NCT04686682","phase":"PHASE1, PHASE2","title":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","status":"RECRUITING","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2021-05-07","conditions":"NSCLC, SCLC, CRPC","enrollment":152},{"nctId":"NCT04603495","phase":"PHASE3","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-09","conditions":"Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":430},{"nctId":"NCT06122831","phase":"PHASE1, PHASE2","title":"A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-12","conditions":"Myelofibrosis","enrollment":92},{"nctId":"NCT05252390","phase":"PHASE1","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Nuvation Bio Inc.","startDate":"2022-03-29","conditions":"Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer","enrollment":82},{"nctId":"NCT02711137","phase":"PHASE1, PHASE2","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-18","conditions":"Solid Tumors","enrollment":137},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT04471974","phase":"PHASE2","title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2021-01-26","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma","enrollment":61},{"nctId":"NCT06401356","phase":"PHASE3","title":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-13","conditions":"Hematologic Malignancy, Solid Tumor, Advanced Malignancies","enrollment":50},{"nctId":"NCT05071937","phase":"PHASE2","title":"ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-04-21","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":33},{"nctId":"NCT06619522","phase":"PHASE2","title":"A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-09-11","conditions":"Myelofibrosis","enrollment":""},{"nctId":"NCT04910152","phase":"PHASE1, PHASE2","title":"Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD","status":"TERMINATED","sponsor":"Hannah Choe, MD","startDate":"2022-04-19","conditions":"Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease","enrollment":2},{"nctId":"NCT05488548","phase":"PHASE1","title":"Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies","status":"RECRUITING","sponsor":"Epigenetix, Inc.","startDate":"2022-12-21","conditions":"Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia","enrollment":75},{"nctId":"NCT06161493","phase":"PHASE1","title":"ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors","status":"WITHDRAWN","sponsor":"Haider Mahdi","startDate":"2024-01-23","conditions":"Ovarian Cancer, Recurrent Solid Tumors","enrollment":""},{"nctId":"NCT03220347","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas","status":"TERMINATED","sponsor":"Celgene","startDate":"2017-07-24","conditions":"Lymphoma, Non-Hodgkin, Neoplasms","enrollment":139},{"nctId":"NCT03936465","phase":"PHASE1","title":"Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-09-27","conditions":"Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric","enrollment":41},{"nctId":"NCT01943851","phase":"PHASE2","title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-14","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT01949883","phase":"PHASE1","title":"A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2013-09-05","conditions":"Lymphoma","enrollment":64},{"nctId":"NCT02157636","phase":"PHASE1","title":"A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-15","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT05678283","phase":"PHASE1","title":"A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-09","conditions":"Advanced Solid Tumors","enrollment":""},{"nctId":"NCT06137651","phase":"PHASE1","title":"Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-12-31","conditions":"Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges","enrollment":""},{"nctId":"NCT02543879","phase":"PHASE1","title":"Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":94},{"nctId":"NCT05677373","phase":"PHASE1, PHASE2","title":"Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma","status":"WITHDRAWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-13","conditions":"Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma","enrollment":""},{"nctId":"NCT04988035","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-03","conditions":"COVID-19","enrollment":201},{"nctId":"NCT05301972","phase":"","title":"Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"","enrollment":""},{"nctId":"NCT02698189","phase":"PHASE1","title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-19","conditions":"AML Including AML de Novo and AML Secondary to MDS, DLBCL","enrollment":9},{"nctId":"NCT02419417","phase":"PHASE1, PHASE2","title":"Study of BMS-986158 in Subjects With Select Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-06-19","conditions":"Advanced Tumors","enrollment":83},{"nctId":"NCT05110807","phase":"PHASE1","title":"A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-05","conditions":"Advanced Malignant Tumors","enrollment":38},{"nctId":"NCT02711956","phase":"PHASE1, PHASE2","title":"A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Zenith Epigenetics","startDate":"2016-12","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":75},{"nctId":"NCT02698176","phase":"PHASE1","title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-04","conditions":"NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC)","enrollment":13},{"nctId":"NCT02296476","phase":"PHASE2","title":"A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)","status":"TERMINATED","sponsor":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-10-29","conditions":"Glioblastoma Multiforme","enrollment":12},{"nctId":"NCT02259114","phase":"PHASE1","title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","status":"COMPLETED","sponsor":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-10-23","conditions":"NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation","enrollment":47},{"nctId":"NCT04116359","phase":"PHASE1, PHASE2","title":"Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-18","conditions":"Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":""},{"nctId":"NCT03925428","phase":"PHASE1","title":"Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-18","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01587703","phase":"PHASE1","title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03-28","conditions":"Carcinoma, Midline","enrollment":196},{"nctId":"NCT03068351","phase":"PHASE1","title":"Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-26","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT02431260","phase":"PHASE1, PHASE2","title":"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2015-04-14","conditions":"Solid Tumors and Hematologic Malignancy","enrollment":69},{"nctId":"NCT02986919","phase":"PHASE2","title":"Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Peripheral Nerve Tumors","enrollment":""},{"nctId":"NCT03266159","phase":"PHASE2","title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-11-27","conditions":"Solid Tumours","enrollment":""},{"nctId":"NCT02705469","phase":"PHASE1","title":"A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Zenith Epigenetics","startDate":"2016-05","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":44},{"nctId":"NCT02303782","phase":"PHASE1, PHASE2","title":"A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)","status":"WITHDRAWN","sponsor":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-01","conditions":"Acute Myeloid Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":732,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BET Inhibitor","genericName":"BET Inhibitor","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins Used for T-cell lymphoma, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}